Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 494,474
  • Shares Outstanding, K 118,864
  • Annual Sales, $ 207,740 K
  • Annual Income, $ -143,590 K
  • 60-Month Beta 1.43
  • Price/Sales 2.46
  • Price/Cash Flow N/A
  • Price/Book 0.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.40
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +19.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +14.92%
on 10/02/19
4.72 -11.86%
on 09/19/19
-0.45 (-9.76%)
since 09/18/19
3-Month
3.50 +18.86%
on 08/06/19
5.77 -27.90%
on 09/11/19
+0.32 (+8.33%)
since 07/18/19
52-Week
3.50 +18.86%
on 08/06/19
10.45 -60.19%
on 12/13/18
-4.60 (-52.51%)
since 10/18/18

Most Recent Stories

More News
Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia(R) for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a fully integrated biopharmaceutical company focused on bettering the lives of people impacted by kidney disease, today filed a complaint in federal district court...

AKBA : 4.16 (-3.26%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees...

AKBA : 4.16 (-3.26%)
Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P....

AKBA : 4.16 (-3.26%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees...

AKBA : 4.16 (-3.26%)
Akebia Therapeutics Announces Full Enrollment of its Global Phase 3 Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced full enrollment of its global Phase 3 program evaluating the safety and efficacy of vadadustat for the treatment of anemia due to chronic kidney...

AKBA : 4.16 (-3.26%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P....

AKBA : 4.16 (-3.26%)
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 4.16 (-3.26%)
Akebia Therapeutics: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $58.2 million in its second quarter.

AKBA : 4.16 (-3.26%)
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today reported financial results...

AKBA : 4.16 (-3.26%)
Akebia Therapeutics(R) Announces Settlement of Auryxia(R) Patent Litigation with Par Pharmaceutical

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and...

KERX : 3.36 (-2.04%)
AKBA : 4.16 (-3.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 4.52
1st Resistance Point 4.34
Last Price 4.16
1st Support Level 4.05
2nd Support Level 3.94

See More

52-Week High 10.45
Fibonacci 61.8% 7.80
Fibonacci 50% 6.97
Fibonacci 38.2% 6.15
Last Price 4.16
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar